Approval · Notice of Compliance 21520 · 2018
DELSTRIGO: Notice of Compliance 21520
Issued November 9, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 21520
- Date
- November 9, 2018
- Company
- Merck Canada IncKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| DELSTRIGO | 02482592 | Marketed |
Medicinal ingredients
- LAMIVUDINE 300 MG per TAB
- TENOFOVIR DISOPROXIL FUMARATE 300 MG per TAB
- DORAVIRINE 100 MG per TAB